Validation of BCMA-CD19 Compound CAR-T Therapy in SLE Overlap Syndrome: Over 1.5-Year Follow-Up.

Highlights a revolutionary cellular therapy approach for achieving drug-free remission in severe, refractory lupus nephritis.